Education
About Us
Working with TipRanks
Follow Us
Mereo Biopharma Group Plc (MREO)
NASDAQ:MREO
Total Valuation
Mereo Biopharma Group Plc has a market cap or net worth of $364.33M. The enterprise value is $281.28M.
Market Cap$364.33M
Enterprise Value$281.28M
Share Statistics
Mereo Biopharma Group Plc has 159,131,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding159,131,700
Owned by Insiders1.32%
Owned by Institutions36.48%
Financial Efficiency
Mereo Biopharma Group Plc’s return on equity (ROE) is -0.71 and return on invested capital (ROIC) is -68.89%.
Return on Equity (ROE)-0.71
Return on Assets (ROA)-0.57
Return on Invested Capital (ROIC)-68.89%
Return on Capital Employed (ROCE)-0.76
Revenue Per Employee0.00
Profits Per Employee-1.20M
Employee Count36
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Mereo Biopharma Group Plc is ―. Mereo Biopharma Group Plc’s PEG ratio is 0.12.
PE Ratio―
PS Ratio0.00
PB Ratio8.49
Price to Fair Value8.49
Price to FCF-15.44
Price to Operating Cash Flow-9.91
PEG Ratio0.12
Income Statement
In the last 12 months, Mereo Biopharma Group Plc had revenue of 0.00 and earned -43.25M in profits. Earnings per share was -0.29.
Revenue0.00
Gross Profit0.00
Operating Income-47.36M
Pretax Income-43.25M
Net Income-43.25M
EBITDA-40.80M
Earnings Per Share (EPS)-0.29
Cash Flow
In the last 12 months, operating cash flow was -32.71M and capital expenditures -320.00K, giving a free cash flow of -33.03M billion.
Operating Cash Flow-32.71M
Free Cash Flow-33.03M
Free Cash Flow per Share-0.21
Dividends & Yields
Mereo Biopharma Group Plc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.09
52-Week Price Change-39.90%
50-Day Moving Average1.96
200-Day Moving Average2.10
Relative Strength Index (RSI)63.20
Average Volume (3m)2.03M
Important Dates
Mereo Biopharma Group Plc upcoming earnings date is Apr 1, 2026, TBA (Confirmed).
Last Earnings DateNov 10, 2025
Next Earnings DateApr 1, 2026
Ex-Dividend Date―
Financial Position
Mereo Biopharma Group Plc as a current ratio of 5.40, with Debt / Equity ratio of 1.11%
Current Ratio5.40
Quick Ratio5.40
Debt to Market Cap0.01
Net Debt to EBITDA1.49
Interest Coverage Ratio-34.56
Taxes
In the past 12 months, Mereo Biopharma Group Plc has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate>-0.01
Enterprise Valuation
Mereo Biopharma Group Plc EV to EBITDA ratio is -10.70, with an EV/FCF ratio of -13.55.
EV to Sales0.00
EV to EBITDA-10.70
EV to Free Cash Flow-13.55
EV to Operating Cash Flow-13.84
Balance Sheet
Mereo Biopharma Group Plc has $48.70M in cash and marketable securities with $397.00K in debt, giving a net cash position of $48.30M billion.
Cash & Marketable Securities$48.70M
Total Debt$397.00K
Net Cash$48.30M
Net Cash Per Share$0.30
Tangible Book Value Per Share$0.41
Margins
Gross margin is 22.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin22.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Mereo Biopharma Group Plc is $6.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.67
Price Target Upside191.27% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast―